Commentary on Nolan etal. (2014): Opiate substitution treatment and hepatitis C virus prevention: Building an evidence base?

Addiction

Volumn 109, Issue 12, 2014, Pages 2060-2061

  Vickerman, Peter ^a   Page, Kimberly ^b   Maher, Lisa ^c   Hickman, Matthew ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Buprenorphine; Hepatitis C; Injecting drug use; Methadone maintenance therapy; Opiate substitution treatment; Prevention

Indexed keywords

BUPRENORPHINE; METHADONE;

HEPACIVIRUS; HUMAN; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS;

BUPRENORPHINE; HEPACIVIRUS; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS;

EID: 84920261717     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12750     Document Type: Note

References (19)

1. MacArthur G. J., Minozzi S., Martin N., Vickerman P., Bruneau J., Davoli M. etal. Evidence for the effectiveness of opiate substitution treatment in relation to HIV transmission in people who inject drugs: a systematic review and meta-analysis. BMJ 2012; 345: 1-16.
2. Cornish R., Macleod J., Strang J., Vickerman P., Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010; 341: c5475.
3. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M. etal. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011; 106: 32-51.
4. Malta M., Strathdee S. A., Magnanini M. F., Bastos F. I. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008; 103: 1242-1257.
5. Lawrinson P., Ali R., Buavirat A., Chiamwongpaet S., Dvoryak S., Habrat B. etal. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008; 103: 1484-1492.
6. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R. J. etal. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-171. iii-iv.
7. Pang L., Hao Y., Mi G., Wang C., Luo W., Rou K. etal. Effectiveness of first eight methadone maintenance treatment clinics in China. AIDS 2007; 21: S103-107.
8. Richardson L., Wood E., Montaner J., Kerr T. Addiction treatment-related employment barriers: the impact of methadone maintenance. J Subst Abuse Treat 2012; 43: 276-284.
9. Hagan H., Pouget E. R., Des Jarlais D. C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204: 74-83.
10. MacArthur G. J., van Velzen E., Palmateer N., Kimber J., Pharris A., Hope V. etal. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy 2014; 25: 34-52.
11. Turner K., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N. etal. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 1978-1988.
12. Nolan S., Dias Lima V., Fairbairn N., Kerr T., Montaner J., Grebely J. etal. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 2014; 109: 2053-2059.
13. White B., Dore G. J., Lloyd A., Rawlinson W., Maher L. Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Med J Aust 2014; 201: 326-329.
14. Tsui J. I., Evans J. E., Lum P. J., Hahn J., Page K. Opioid agonist therapy is associated with lower incidence of hepatitis C virus infection in young adult persons who inject drugs. JAMA 2014; doi: 10.1001/jamainternmed.2014.5416. [Epub a head of print].
15. Vickerman P., Martin N., Turner K., Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic settings. Addiction 2012; 107: 1984-1995.
16. Mathers B. M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R. P. etal. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 1014-1028.
17. Degenhardt L., Mathers B. M., Wirtz A. L., Wolfe D., Kamarulzaman A., Carrieri M. P. etal. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. Int J Drug Policy 2014; 25: 53-60.
18. Martin N. K., Hickman M., Hutchinson S. J., Goldberg D. J., Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57: S39-45.
19. Hahn J. A., Wylie D., Dill J., Sanchez M. S., Lloyd-Smith J. O., Page-Shafer K. etal. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics 2009; 1: 47-57.